Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143Phase 3Completed
- Lead sponsor
- Biohaven Pharmaceuticals, Inc. (Industry)
- Enrollment
- 456 (actual)
- Start date
- 22 Dec 2020
- Primary completion
- 27 Oct 2025 (actual)
- Study completion
- 27 Oct 2025
- Last update posted
- 7 Jan 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Troriluzole Drug
- Placebo Drug
Conditions and primary outcome
- Obsessive-Compulsive Disorder
Primary outcome
The total score on the Yale-Brown Obsessive Compulsive Scale (YBOCS) (Change in total score from baseline, assessed at screening, baseline, week 4, 8 &10)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT04641143.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04641143 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.